Renaissance Group LLC bought a new stake in Amedisys Inc (NASDAQ:AMED) in the first quarter, Holdings Channel reports. The institutional investor bought 3,897 shares of the health services provider’s stock, valued at approximately $480,000.
A number of other institutional investors have also recently modified their holdings of the stock. Commonwealth Equity Services LLC lifted its position in shares of Amedisys by 2.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 3,704 shares of the health services provider’s stock worth $433,000 after purchasing an additional 95 shares during the period. Jennison Associates LLC lifted its stake in Amedisys by 2.0% in the fourth quarter. Jennison Associates LLC now owns 6,408 shares of the health services provider’s stock worth $750,000 after acquiring an additional 126 shares during the last quarter. First Hawaiian Bank lifted its stake in Amedisys by 45.6% in the fourth quarter. First Hawaiian Bank now owns 415 shares of the health services provider’s stock worth $49,000 after acquiring an additional 130 shares during the last quarter. ETRADE Capital Management LLC lifted its stake in Amedisys by 2.2% in the fourth quarter. ETRADE Capital Management LLC now owns 6,819 shares of the health services provider’s stock worth $799,000 after acquiring an additional 148 shares during the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in Amedisys by 1.8% in the fourth quarter. State of Alaska Department of Revenue now owns 9,723 shares of the health services provider’s stock worth $1,138,000 after acquiring an additional 175 shares during the last quarter. 92.07% of the stock is owned by institutional investors and hedge funds.
In other news, insider David B. Pearce sold 4,370 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $120.01, for a total transaction of $524,443.70. Following the completion of the sale, the insider now directly owns 13,129 shares of the company’s stock, valued at approximately $1,575,611.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christopher Gerard sold 2,500 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $118.96, for a total value of $297,400.00. Following the sale, the chief operating officer now directly owns 25,731 shares of the company’s stock, valued at $3,060,959.76. The disclosure for this sale can be found here. Insiders sold a total of 8,281 shares of company stock valued at $993,393 in the last quarter. 2.60% of the stock is currently owned by corporate insiders.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.22. Amedisys had a return on equity of 29.45% and a net margin of 7.14%. The business had revenue of $467.34 million during the quarter, compared to analyst estimates of $460.83 million. During the same quarter last year, the company posted $0.79 EPS. Amedisys’s revenue for the quarter was up 17.0% on a year-over-year basis. Equities analysts predict that Amedisys Inc will post 4.05 earnings per share for the current year.
A number of research analysts recently issued reports on the stock. SunTrust Banks lifted their price target on shares of Amedisys to $145.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research lowered Amedisys from a “buy” rating to a “hold” rating in a report on Monday, January 28th. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 14th. ValuEngine lowered Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 27th. Finally, Benchmark lowered Amedisys from a “buy” rating to a “hold” rating and set a $136.64 target price on the stock. in a report on Tuesday, February 5th. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Amedisys currently has a consensus rating of “Hold” and an average target price of $125.90.
WARNING: “Renaissance Group LLC Buys New Stake in Amedisys Inc (AMED)” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://weekherald.com/2019/05/03/renaissance-group-llc-buys-new-stake-in-amedisys-inc-amed.html.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Story: Conference Calls
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.